Who
David Zaccardelli
Director
Company insider
Files Form 4 as: Director, Vor Biopharma; Director, SAB Biotherapeutics; President and CEO, Verona Pharma; President & CEO, Dova Pharmaceuticals; Acting Chief Executive Officer, Melinta Therapeutics, Inc. /new/; EVP & Chief Operating Officer, United Therapeutics.
In numbers
- Trades disclosed
- 273
- Buys
- 2
- Sells
- 65
- Bought
- $261K
- Sold
- $45.9M
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 2 Jan 2015
- Last trade
- 7 Jul 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 9 Jul 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,658 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,658 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —800,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —389,792 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —445,536 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code A | —1,649,952 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —1,649,952 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code D | —12,176,144 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code M | —3,285,280 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code D | —3,285,280 | filing |
| 29 Aug 2025filed 3 Sep 2025 | Verona Pharma | SEC FORM 4 Code G | —1,200,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —55,696 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharma | SEC FORM 4 Code M | —255,696 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharma | SEC FORM 4 Sold | $2.7M208,912 at $13.14 | filing |
| 8 Jul 2025filed 9 Jul 2025 | Verona Pharma | SEC FORM 4 Code F | $1.0M90,320 at $11.44 | filing |
| 7 Jul 2025filed 9 Jul 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code A | —675,048 at $0.00 | filing |
| 7 Jul 2025filed 9 Jul 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —229,512 at $0.00 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)UTHR · dailypolitical.com · 18 Oct 2026United Therapeutics (NASDAQ: UTHR) general counsel sells 8,300 shares under planUTHR · themarketsdaily.com · 17 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)UTHR · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name David Zaccardelli; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.